No Data
H.C. Wainwright Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $5
Promising Preclinical Data and Strategic Trial Design Support Buy Rating for Context Therapeutics
Context Therapeutics: A Promising Investment in Innovative Oncology Therapies With Strong Financial Position
H.C. Wainwright Maintains Context Therapeutics(CNTX.US) With Buy Rating, Cuts Target Price to $5
Express News | Context Therapeutics Inc. : H.c. Wainwright Cuts Target Price to $5 From $6
Express News | Context Therapeutics Files for Mixed Shelf of up to $250 Mln - SEC Filing
No Data
No Data